Login to Your Account



Other News To Note


Thursday, March 22, 2012
• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, received orphan drug designation from the FDA for its candidate for carcinoid syndrome, telotristat etiprate (LX1032). Lexicon reported positive Phase II results in August 2011 and is preparing a global Phase III development plan.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription